ISPCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
iSpecimen Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.91−0.01 (-0.75%)
Close on Oct 19, 2026
- Market cap
- $1.27M
- P/E (TTM)
- –
- Dividend yield
- –
iSpecimen statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Commercial Physical & Biological Research companies for comparison
Valuation
| Measure | iSpecimen | Industry median |
|---|---|---|
| Market Cap | $2.29M | $73.61M |
| Enterprise Value | -$2.12M | $55.54M |
| PS Ratio | 4.92 | 3.25 |
| PB Ratio | 1.32 | 3.13 |
| P/TBV Ratio | 1.32 | 8.30 |
Enterprise value
| Measure | iSpecimen | Industry median |
|---|---|---|
| EV / Sales | -4.55 | 2.79 |
Income (trailing twelve months)
| Measure | iSpecimen | Industry median |
|---|---|---|
| Revenue | $466.30K | $24.74M |
| Gross Profit | -$456.94K | $19.54M |
| Operating Income | -$9.42M | -$55.64K |
| Net Income | -$11.42M | -$97.64K |
| EBITDA | -$8.22M | -$29.48K |
| EPS (Diluted) | -$52.78 | $0.00 |
Margins
| Measure | iSpecimen | Industry median |
|---|---|---|
| Gross Margin | -98.0% | 40.4% |
| Operating Margin | -2020.0% | 0.94% |
| Profit Margin | -2449.0% | 0.51% |
| EBITDA Margin | -1762.1% | 3.48% |
Returns
| Measure | iSpecimen | Industry median |
|---|---|---|
| Return on Equity (ROE) | -968.5% | 0.45% |
| Return on Assets (ROA) | -170.1% | -3.47% |
| Return on Capital Employed (ROCE) | -491.6% | 2.03% |
Growth
| Measure | iSpecimen | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -92.1% | 4.26% |
| Revenue Growth (3Y CAGR) | -43.0% | 2.15% |
| Revenue Growth (5Y CAGR) | -25.1% | 7.37% |
Balance sheet
| Measure | iSpecimen | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.41M | $5.43M |
| Net Cash (Debt) | $4.41M | $17.62K |
| Net Cash Per Share | $1.75 | $0.00 |
| Equity (Book Value) | $1.74M | $10.50M |
| Book Value Per Share | $0.69 | $0.60 |
| Tangible Book Value | $1.74M | -$78.36K |
| Working Capital | -$992.54K | $2.78M |
Financial position
| Measure | iSpecimen | Industry median |
|---|---|---|
| Current Ratio | 0.82 | 1.26 |
| Quick Ratio | 0.81 | 0.65 |
Cash flow (trailing twelve months)
| Measure | iSpecimen | Industry median |
|---|---|---|
| Operating Cash Flow | -$7.00M | $8.04K |
Efficiency
| Measure | iSpecimen | Industry median |
|---|---|---|
| Asset Turnover | 0.07 | 0.83 |
| Revenue Per Employee | $8.80K | $216.23K |
| Profits Per Employee | -$215.47K | -$1.99K |
| Employee Count | 53 | 115 |
Dividends and yields
| Measure | iSpecimen | Industry median |
|---|---|---|
| Earnings Yield | -498.2% | -1.29% |
Shares
| Measure | iSpecimen | Industry median |
|---|---|---|
| Shares Outstanding | 2,518,590 | 29,217,800 |
| Shares Change (YoY) | 1150.0% | 0.84% |
| Shares Change (QoQ) | 105.3% | 0.00% |
| Float | 2,518,590 | 26,226,050 |
| Shares Held by Insiders | 0.00% | 4.85% |
| Shares Held by Institutions | 2.26% | 83.3% |
Scores
| Measure | iSpecimen | Industry median |
|---|---|---|
| Altman Z-Score | -20.34 | 2.64 |
| Piotroski F-Score | 3 | 5 |
| Beneish M-Score | -5.94 | -2.75 |
Calculated by StockData from iSpecimen's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.